(Bold for FDA approved)
• For migraine, proposed mechanisms include inhibition of the adrenergic pathway, interaction with the serotonin system and receptors, inhibition of nitric oxide synthesis, and normalization of contingent negative variation
• For tremor, antagonism of peripheral beta 2 receptors is the proposed mechanism
• For PTSD, blockade of beta 1 adrenergic receptors may theoretically prevent fear conditioning and reconsolidation of fear
• For violence/aggression, the mechanism is poorly established; presumed to be related to central actions at beta adrenergic and serotonin receptors
• For migraine, can begin to work within 2 weeks, but may take up to 3 months on a stable dose to see full effect
• For tremor, can begin to work within days
• Bradycardia, hypotension, hyper- or hypoglycemia, weight gain
• Bronchospasm, cold/flu symptoms, sinusitis, pneumonias
• Dizziness, vertigo, fatigue/tiredness, depression, sleep disturbances
• Sexual dysfunction, decreased libido, dysuria, urinary retention, joint pain
• Exacerbation of symptoms in peripheral vascular disease and Raynaud’s syndrome
• In acute congestive heart failure, may further depress myocardial contractility
• Can blunt premonitory symptoms of hypoglycemia in diabetes and mask clinical signs of hyperthyroidism
• Nonselective beta blockers such as propranolol can inhibit bronchodilation, making them contraindicated in asthma, severe COPD
• Do not use in pheochromocytoma unless alpha blockers are already being used
• Risk of excessive myocardial depression in general anesthesia
common
common
• Lower dose, change to an extended-release formulation, or switch to another agent
• 40–400 mg/day
• Tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg, 90 mg
• Extended-release capsule 60 mg, 80 mg, 120 mg, 160 mg
• Oral solution 4 mg/mL, 8 mg/mL
• Injection 1 mg/mL
• Safe
• No
• No dose adjustment necessary
• Use with caution with severe impairment; dose reduction may be necessary
• Do not use in acute shock, myocardial infarction, hypotension, and greater than first-degree heart block, but indicated in clinically stable patients post-myocardial infarction to reduce risk of re-infarction starting 1–4 weeks after event
• Use with caution
• May increase risk of stroke
• Usual dose in children is 2–4 mg/kg in 2 divided doses; maximum 16 mg/kg/day
• Clinical trials for migraine prophylaxis did not include children
• Controlled studies have not been conducted in pregnant women
• May reduce perfusion of the placenta
• Use only if potential benefits outweigh the potential risks to the fetus
• Some drug is found in mother’s breast milk
• Due to high lipid solubility, propranolol is found in breast milk more than many other beta blockers
• Recommended either to discontinue drug or bottle feed unless the potential benefit to the mother justifies the potential risk to the child
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera